THER ADV MED ONCOL 2020 10.1177/1758835920926796
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J

Transl Cancer Res 2020 10.21037/tcr-19-1876
Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152941
CDH1 mutations in gastric cancers are not associated with family history
Choi1, S; Jang, J; Heo, YJ; Kang, SY; Kim, ST; Lee, J; Kang, WK; Kim, JW; Kim, KM

Transl Cancer Res 2020 10.21037/tcr.2020.04.07
Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)
Byeon1, S; Kang, MJ; Choi, YJ; Kim, YJ; Kim, M; Yun, J; Yi, SY; Kim, JY; Kim, ST; Lee, J

TARGET ONCOL 2020 10.1007/s11523-020-00706-0
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CANCERS 2020 10.3390/cancers12040943
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
Yu1, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH

TARGET ONCOL 2020 10.1007/s11523-020-00713-1
Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients
Kim1, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152881
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
Liu1, XQ; Choi, MG; Kim, K; Kim, KM; Kim, ST; Park, SH; Cristescu, R; Peter, S; Lee, J

PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820
TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer
Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK

ESMO OPEN 2020 10.1136/esmoopen-2020-000670
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J

Front Oncol 2020 10.3389/fonc.2020.00314
Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
Kim1, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM

TARGET ONCOL 2020 10.1007/s11523-019-00691-z
Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS

VIRCHOWS ARCH 2020 10.1007/s00428-019-02653-2
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation
Kim1, HN; Jang, J; Heo, YJ; Kim, B; Jung, HR; Jang, Y; Kang, SY; Kim, ST; Lee, JY; Kang, WK; Kim, KM

Front Oncol 2020 10.3389/fonc.2020.00225
A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling
Chao1, JS; Lee, J; Kim, K; Kang, SY; Lee, T; Kim, KM; Kim, ST; Klempner, SJ; Lee, H

Genome Med 2020 10.1186/s13073-020-0717-8
Comprehensive pharmacogenomic characterization of gastric cancer
Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J

J ONCOL 2020 10.1155/2020/4659062
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO

PATHOL RES PRACT 2020 10.1016/j.prp.2019.152734
Correlation between RICTOR overexpression and amplification in advanced solid tumors
Bang1, H; Ahn, S; Kim, EJ; Kim, ST; Park, H; Lee, J; Kim, KM

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1324
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Willis1, J; Lefterova, MI; Artyomenko, A; Kasi, PM; Nakamura, Y; Mody, K; Catenacci, DVT; Fakih, M; Barbacioru, C; Zhao, J; Sikora, M; Fairclough, SR; Lee, H; Kim, KM; Kim, ST; Kim, J; Gavino, D; Benavides, M; Peled, N; Nguyen, T; Cusnir, M; Eskander, RN; Azzi, G; Yoshino, T; Banks, KC; Raymond, VM; Lanman, RB; Chudova, DI; Talasaz, A; Kopetz, S; Lee, J; Odegaard, JI

CLIN CANCER RES 2019 10.1158/1078-0432.CCR-19-1704
Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Maron1, SB; Chase, LM; Lomnicki, S; Kochanny, S; Moore, KL; Joshi, SS; Landron, S; Johnson, J; Kiedrowski, LA; Nagy, RJ; Lanman, RB; Kim, ST; Lee, J; Catenacci, DVT

INT J CANCER 2019 10.1002/ijc.32228
Bridging genomics and phenomics of gastric carcinoma
Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM

ONCOLOGIST 2019 10.1634/theoncologist.2019-0121
FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
Klempner1, SJ; Madison, R; Pujara, V; Ross, JS; Miller, VA; Ali, SM; Schrock, AB; Kim, ST; Maron, SB; Dayyani, F; Catenacci, DVT; Lee, J; Chao, J

TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017
Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study
Kwon1, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM

Front Oncol 2019 10.3389/fonc.2019.01327
Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening
Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J

J Cancer 2019 10.7150/jca.37610
Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial
Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY

J IMMUNOTHER 2019 10.1097/CJI.0000000000000283
LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target
Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST

ANTICANCER RES 2019 10.21873/anticanres.13785
Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

SCI REP-UK 2019 10.1038/s41598-019-51981-5
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C

CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK

ONCOLOGIST 2019 10.1634/theoncologist.2019-0221
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities
Kim1, YS; Ji, JH; Oh, SY; Lee, S; Huh, SJ; Lee, JH; Song, KH; Son, CH; Roh, MS; Lee, GW; Lee, J; Kim, ST; Kim, CK; Jang, JS; Hwang, IG; Ahn, HK; Park, LC; Oh, SY; Kim, SG; Lee, SC; Lim, DH; Lee, SI; Kang, JH

Transl Cancer Res 2019 10.21037/tcr.2019.09.27
Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

THER ADV MED ONCOL 2019 10.1177/1758835919871126
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
Yoo1, C; Im, HS; Kim, KP; Oh, DY; Lee, KH; Chon, HJ; Kim, JH; Kang, M; Kim, I; Lee, GJ; Oh, SY; Choi, Y; Choi, HJ; Kim, ST; Park, JO; Ryoo, BY

BMC CANCER 2019 10.1186/s12885-019-6030-5
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
Lee1, J; Lee, SJ; Kim, K; Kim, ST; Lee, J

PATHOL RES PRACT 2019 10.1016/j.prp.2019.152434
CCNE1 amplification is associated with liver metastasis in gastric carcinoma
Kim1, B; Shin, HC; Heo, YJ; Ha, SY; Jang, KT; Kim, ST; Kang, WK; Lee, J; Kim, KM

CANCER RES TREAT 2019 10.4143/crt.2018.379
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK

Am J Transl Res 2019
Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification
Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J

CANCER RES TREAT 2019 10.4143/crt.2018.401
Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols
Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K

J MOL DIAGN 2019 10.1016/j.jmoldx.2019.02.007
Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing A Direct Comparison Study with Immunohistochemistry
Choi1, S; Chu, J; Kim, B; Ha, SY; Kim, ST; Lee, J; Kang, WK; Han, H; Sohn, I; Kim, KM

J Cancer 2019 10.7150/jca.30355
The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma
Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

J Cancer 2019 10.7150/jca.30257
High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer
Kim1, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

ONCOLOGY-BASEL 2019 10.1159/000499628
Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial
Miceli1, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J

ANN ONCOL 2019 10.1093/annonc/mdz058
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY

PLoS One 2019 10.1371/journal.pone.0215080
Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J

TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009
Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J

Front Oncol 2019 10.3389/fonc.2019.00212
Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
Lee1, J; Franovic, A; Shiotsu, Y; Kim, ST; Kim, KM; Banks, KC; Raymond, VM; Lanman, RB

J Cancer 2019 10.7150/jca.29106
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

PATHOL RES PRACT 2019 10.1016/j.prp.2018.11.010
MET is overexpressed in microsatellite instability-high gastric carcinoma
Sim1, J; Heo, YJ; Bae, H; Shin, HC; Kim, B; Cho, J; Kim, ST; Lee, J; Kang, WK; Kim, KM

CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y
Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H

ANN ONCOL 2019 10.1093/annonc/mdy550
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
Sundar1, R; Huang, KK; Qamra, A; Kim, KM; Kim, ST; Kang, WK; Tan, ALK; Lee, J; Tan, P

Oncoimmunology 2019 10.1080/2162402X.2018.1544442
PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer
Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E

OncoTargets and therapy 2019 10.2147/OTT.S187621
The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

J Gastric Cancer 2018 10.5230/jgc.2018.18.e34
Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial
Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH

BMC CANCER 2018 10.1186/s12885-018-4995-0
Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line
Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO

SCI REP-UK 2018 10.1038/s41598-018-34858-x
SEPROGADIC-serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy
Ahn1, HS; Sohn, TS; Kim, MJ; Cho, BK; Kim, SM; Kim, ST; Yi, EC; Lee, C

RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002
Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer
Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S

NAT GENET 2018 10.1038/s41588-018-0209-6
Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy
Lee1, JK; Liu, ZQ; Sa, JK; Shin, S; Wang, JG; Bordyuh, M; Cho, H; Elliott, O; Chu, T; Choi, SW; Rosenbloom, DIS; Lee, IH; Shin, YJ; Kang, HJ; Kim, D; Kim, SY; Sim, MH; Kim, J; Lee, T; Seo, YJ; Shin, H; Lee, M; Kim, SH; Kwon, YJ; Oh, JW; Song, M; Kim, M; Kong, DS; Choi, JW; Seol, HJ; Lee, JI; Kim, ST; Park, JO; Kim, KM; Song, SY; Lee, JW; Kim, HC; Lee, JE; Choi, MG; Seo, SW; Shim, YM; Zo, JI; Jeong, BC; Yoon, Y; Ryu, GH; Kim, NKD; Bae, JS; Park, WY; Lee, J; Verhaak, RGW; Iavarone, A; Lee, J; Rabadan, R; Nam, DH

NAT MED 2018 10.1038/s41591-018-0101-z
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013
c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival
Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

J Cancer 2018 10.7150/jca.26068
Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST

J Cancer 2018 10.7150/jca.26256
NCOA4-RET fusion in colorectal cancer: Therapeutic challenge using patient-derived tumor cell lines
Kim1, SY; Oh, SO; Kim, K; Lee, J; Kang, S; Kim, KM; Lee, W; Kim, ST; Nam, DN

J Cancer 2018 10.7150/jca.24948
Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial
Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer
Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS

ANN ONCOL 2018 10.1093/annonc/mdy090
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
Pietrantonio1, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Morano, F; Fuca, G; Nikolinakos, P; Drilon, A; Hechtman, JF; Christiansen, J; Gowen, K; Frampton, GM; Gasparini, P; Rossini, D; Gigliotti, C; Kim, ST; Prisciandaro, M; Hodgson, J; Zaniboni, A; Chiu, VK; Milione, M; Patel, R; Miller, V; Bardelli, A; Novara, L; Wang, L; Pupa, SM; Sozzi, G; Ross, J; Di Bartolomeo, M; Bertotti, A; Ali, S; Trusolino, L; Falcone, A; de Braud, F; Cremolini, C

ANN ONCOL 2018 10.1093/annonc/mdy034
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients
Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J

TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007
The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer
Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY

J Cancer 2018 10.7150/jca.25132
The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO

ONCOLOGIST 2018 10.1634/theoncologist.2017-0528
Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors
Lee1, KW; Lee, DH; Kang, JH; Park, JO; Kim, SH; Hong, YS; Kim, ST; Oh, DY; Bang, YJ

J NATL CANCER I 2017 10.1093/jnci/djx089
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Pietrantonio1, F; Di Nicolantonio, F; Schrock, AB; Lee, J; Tejpar, S; Sartore-Bianchi, A; Hechtman, JF; Christiansen, J; Novara, L; Tebbutt, N; Fuca, G; Antoniotti, C; Kim, ST; Murphy, D; Berenato, R; Morano, F; Sun, J; Min, BS; Stephens, PJ; Chen, M; Cremolini, C

ONCOTARGET 2017 10.18632/oncotarget.22394
MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.18182
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer
Ahn1, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J

ONCOLOGIST 2017 10.1634/theoncologist.2017-0129
Antiemetic Corticosteroid Rotation from Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated with Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial
Go1, SI; Koo, DH; Kim, ST; Song, HN; Kim, RB; Jang, JS; Oh, SY; Lee, KH; Lee, SI; Kim, SG; Park, LC; Lee, SC; Park, BB; Ji, JH; Yi, SY; Lee, YG; Yun, J; Bruera, E; Hwang, IG; Kang, JH

Oncoimmunology 2017 10.1080/2162402X.2017.1356150
Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity
Park1, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM

ONCOTARGET 2017 10.18632/oncotarget.3750
MerTK is a novel therapeutic target in gastric cancer
Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J

NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

ONCOLOGIST 2017 10.1634/theoncologist.2017-0020
Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials
Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J

Clin Transl Oncol 2017 10.1007/s12094-017-1662-x
Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma
Cho1, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J

ONCOTARGET 2017 10.18632/oncotarget.19985
Development of mesenchymal subtype gene signature for clinical application in gastric cancer
Lee1, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK

ONCOTARGET 2017 10.18632/oncotarget.18168
The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST

ONCOTARGET 2017 10.18632/oncotarget.20492
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J

J Cancer 2017 10.7150/jca.18286
The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS

J Cancer 2017 10.7150/jca.19458
The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST

J Cancer 2017 10.7150/jca.19582
MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines
Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST

EUR RADIOL 2017 10.1007/s00330-016-4644-4
Disappearing or residual tiny (ae<currency>5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?
Kim1, SS; Song, KD; Kim, YK; Kim, HC; Huh, JW; Park, YS; Park, JO; Kim, ST

TUMORI 2017 10.5301/tj.5000666
Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer
Yu1, JI; Park, HC; Lim, DH; Park, JO; Park, YS; Kim, ST; Choi, SH; Choi, DW; Han, IW; Heo, JS

BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6.
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.

Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669.
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519.
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
Cho J11, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.

Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788.
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
Kim SY11, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.

Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362.
Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer
Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.

Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700.
The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

Am J Ther. 2016 Nov/Dec;23(6):e1449-e1455.
A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin
Lee SY11, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S.

J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016.
To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients
Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.

Transl Oncol. 2016 Oct;9(5):466-471. doi: 10.1016/j.tranon.2016.08.009.
Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma
Cho J11, Lee J1, Kim J1, Kim ST1, Lee S1, Kim SY1, Ha SY2, Park CK3, Lim HY4.

Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27.
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival
Ahn S11,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.

Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445.
Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy
Yu JI11, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.

Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4.
A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer
Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.

Transl Oncol. 2016 Jun;9(3):197-202. doi: 10.1016/j.tranon.2016.03.008. Epub 2016 May 12.
BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
Kim HK11, Kim SY1, Lee SJ1, Kang M1, Kim ST1, Jang J1, Rath O2, Schueler J2, Lee DW3, Park WY4, Kim SJ5, Park SH1, Lee J6.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16.
Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.

Onco Targets Ther. 2016 Jun 1;9:3307-12. doi: 10.2147/OTT.S104511. eCollection 2016.
The prognostic role of serum C-X-C chemokine receptor type 4 in patients with metastatic or recurrent colorectal cancer
Choi YJ11, Chang WJ1, Shin SW1, Park KH1, Kim ST2, Kim YH1.

Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22.
Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing
Yoo KH11, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.

Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26.
Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma
Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.

J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016.
Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era
Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.

Medicine (Baltimore). 2016 May;95(19):e3534. doi: 10.1097/MD.0000000000003534.
The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution
Kim ST11, Ha SY, Lee J, Hong SN, Chang DK, Kim YH, Park YA, Huh JW, Cho YB, Yun SH, Lee WY, Kim HC, Park YS.

Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175.
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.

Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526.
Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment
Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.

Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10.
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6